Sangamo Non Current Liabilities Total vs Total Current Liabilities Analysis

SGMO Stock

USD 0.52 0.02 4.00%

Sangamo Therapeutics financial indicator trend analysis is much more than just breaking down Sangamo Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sangamo Therapeutics is a good investment. Please check the relationship between Sangamo Therapeutics Non Current Liabilities Total and its Total Current Liabilities accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

Non Current Liabilities Total vs Total Current Liabilities

Non Current Liabilities Total vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sangamo Therapeutics Non Current Liabilities Total account and Total Current Liabilities. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Sangamo Therapeutics' Non Current Liabilities Total and Total Current Liabilities is 0.97. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Sangamo Therapeutics, assuming nothing else is changed. The correlation between historical values of Sangamo Therapeutics' Non Current Liabilities Total and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Sangamo Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Current Liabilities Total i.e., Sangamo Therapeutics' Non Current Liabilities Total and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.97

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Non Current Liabilities Total

Total Current Liabilities

Total Current Liabilities is an item on Sangamo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Sangamo Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Sangamo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.As of the 27th of April 2024, Selling General Administrative is likely to grow to about 64.2 M, though Tax Provision is likely to grow to (4.3 M).

	2021	2022	2023	2024 (projected)
Gross Profit	110.7M	111.3M	154.0M	161.7M
Total Revenue	110.7M	111.3M	176.2M	185.0M

Gross Profit Total Revenue

Sangamo Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Debt	Other Current Assets	Property Plant Equipment
Total Assets		0.97	-0.4	0.89	0.53	0.62	0.97	0.8	0.73	0.95	0.91	0.42	0.89	0.94	0.36	0.96	0.41	0.06	0.89	0.97	0.75	0.97	0.03	-0.78	0.63	0.51
Total Stockholder Equity	0.97		-0.31	0.81	0.46	0.56	0.89	0.73	0.64	0.86	0.84	0.32	0.83	0.88	0.25	0.96	0.54	-0.06	0.91	0.9	0.65	0.97	-0.1	-0.74	0.5	0.42
Retained Earnings	-0.4	-0.31		-0.41	-0.98	-0.96	-0.48	-0.79	-0.86	-0.56	-0.6	-0.87	-0.46	-0.51	-0.96	-0.22	0.0	-0.13	-0.11	-0.45	-0.84	-0.32	-0.22	0.19	-0.88	-0.86
Other Assets	0.89	0.81	-0.41		0.49	0.58	0.92	0.8	0.71	0.93	0.94	0.52	0.83	0.95	0.38	0.79	0.31	0.23	0.69	0.9	0.8	0.79	0.19	-0.72	0.73	0.46
Common Stock Shares Outstanding	0.53	0.46	-0.98	0.49		0.99	0.58	0.84	0.89	0.65	0.67	0.86	0.56	0.61	0.93	0.37	0.08	0.06	0.26	0.56	0.88	0.46	0.14	-0.29	0.89	0.86
Other Stockholder Equity	0.62	0.56	-0.96	0.58	0.99		0.66	0.89	0.93	0.73	0.76	0.85	0.64	0.69	0.91	0.46	0.15	0.09	0.35	0.64	0.92	0.55	0.16	-0.37	0.91	0.87
Total Liab	0.97	0.89	-0.48	0.92	0.58	0.66		0.84	0.79	0.99	0.93	0.51	0.89	0.95	0.46	0.92	0.26	0.18	0.82	1.0	0.81	0.92	0.16	-0.78	0.73	0.57
Short Long Term Debt Total	0.8	0.73	-0.79	0.8	0.84	0.89	0.84		0.93	0.88	0.93	0.69	0.78	0.87	0.77	0.65	0.35	0.22	0.54	0.82	0.96	0.71	0.25	-0.53	0.87	0.8
Other Current Liab	0.73	0.64	-0.86	0.71	0.89	0.93	0.79	0.93		0.83	0.86	0.75	0.77	0.77	0.87	0.57	0.11	0.24	0.47	0.77	0.95	0.67	0.28	-0.54	0.9	0.93
Total Current Liabilities	0.95	0.86	-0.56	0.93	0.65	0.73	0.99	0.88	0.83		0.95	0.59	0.9	0.96	0.54	0.88	0.22	0.18	0.77	0.97	0.86	0.88	0.17	-0.77	0.8	0.63
Property Plant And Equipment Net	0.91	0.84	-0.6	0.94	0.67	0.76	0.93	0.93	0.86	0.95		0.61	0.87	0.97	0.57	0.78	0.39	0.24	0.66	0.91	0.92	0.8	0.23	-0.69	0.82	0.67
Accounts Payable	0.42	0.32	-0.87	0.52	0.86	0.85	0.51	0.69	0.75	0.59	0.61		0.39	0.56	0.83	0.23	-0.02	0.22	0.15	0.48	0.81	0.31	0.28	-0.15	0.9	0.69
Cash	0.89	0.83	-0.46	0.83	0.56	0.64	0.89	0.78	0.77	0.9	0.87	0.39		0.88	0.45	0.83	0.17	0.08	0.67	0.88	0.76	0.83	0.07	-0.94	0.68	0.62
Non Current Assets Total	0.94	0.88	-0.51	0.95	0.61	0.69	0.95	0.87	0.77	0.96	0.97	0.56	0.88		0.48	0.83	0.4	0.2	0.7	0.94	0.87	0.84	0.18	-0.74	0.77	0.58
Non Currrent Assets Other	0.36	0.25	-0.96	0.38	0.93	0.91	0.46	0.77	0.87	0.54	0.57	0.83	0.45	0.48		0.17	-0.11	0.31	0.06	0.45	0.83	0.28	0.4	-0.18	0.87	0.91
Cash And Short Term Investments	0.96	0.96	-0.22	0.79	0.37	0.46	0.92	0.65	0.57	0.88	0.78	0.23	0.83	0.83	0.17		0.37	-0.05	0.96	0.92	0.56	0.98	-0.09	-0.78	0.45	0.33
Net Receivables	0.41	0.54	0.0	0.31	0.08	0.15	0.26	0.35	0.11	0.22	0.39	-0.02	0.17	0.4	-0.11	0.37		-0.1	0.41	0.27	0.23	0.39	-0.13	-0.06	-0.01	-0.04
Common Stock Total Equity	0.06	-0.06	-0.13	0.23	0.06	0.09	0.18	0.22	0.24	0.18	0.24	0.22	0.08	0.2	0.31	-0.05	-0.1		-0.09	0.19	0.3	-0.02	0.99	-0.03	0.33	0.24
Short Term Investments	0.89	0.91	-0.11	0.69	0.26	0.35	0.82	0.54	0.47	0.77	0.66	0.15	0.67	0.7	0.06	0.96	0.41	-0.09		0.83	0.42	0.95	-0.14	-0.62	0.3	0.23
Non Current Liabilities Total	0.97	0.9	-0.45	0.9	0.56	0.64	1.0	0.82	0.77	0.97	0.91	0.48	0.88	0.94	0.45	0.92	0.27	0.19	0.83		0.79	0.93	0.16	-0.77	0.71	0.55
Property Plant And Equipment Gross	0.75	0.65	-0.84	0.8	0.88	0.92	0.81	0.96	0.95	0.86	0.92	0.81	0.76	0.87	0.83	0.56	0.23	0.3	0.42	0.79		0.63	0.34	-0.53	0.96	0.84
Total Current Assets	0.97	0.97	-0.32	0.79	0.46	0.55	0.92	0.71	0.67	0.88	0.8	0.31	0.83	0.84	0.28	0.98	0.39	-0.02	0.95	0.93	0.63		-0.05	-0.75	0.51	0.44
Common Stock	0.03	-0.1	-0.22	0.19	0.14	0.16	0.16	0.25	0.28	0.17	0.23	0.28	0.07	0.18	0.4	-0.09	-0.13	0.99	-0.14	0.16	0.34	-0.05		0.01	0.37	0.31
Net Debt	-0.78	-0.74	0.19	-0.72	-0.29	-0.37	-0.78	-0.53	-0.54	-0.77	-0.69	-0.15	-0.94	-0.74	-0.18	-0.78	-0.06	-0.03	-0.62	-0.77	-0.53	-0.75	0.01		-0.46	-0.4
Other Current Assets	0.63	0.5	-0.88	0.73	0.89	0.91	0.73	0.87	0.9	0.8	0.82	0.9	0.68	0.77	0.87	0.45	-0.01	0.33	0.3	0.71	0.96	0.51	0.37	-0.46		0.81
Property Plant Equipment	0.51	0.42	-0.86	0.46	0.86	0.87	0.57	0.8	0.93	0.63	0.67	0.69	0.62	0.58	0.91	0.33	-0.04	0.24	0.23	0.55	0.84	0.44	0.31	-0.4	0.81

Click cells to compare fundamentals

Sangamo Therapeutics Account Relationship Matchups

Sangamo Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	637.5M	938.6M	721.9M	562.5M	165.3M	218.1M
Total Stockholder Equity	432.7M	497.4M	375.3M	295.0M	82.9M	144.6M
Retained Earnings	(657.0M)	(778.0M)	(956.3M)	(1.1B)	(1.4B)	(1.3B)
Other Assets	10.6M	15.1M	16.8M	18.5M	1.0	0.95
Common Stock Shares Outstanding	112.1M	134.4M	144.6M	154.3M	174.4M	183.2M
Liabilities And Stockholders Equity	637.5M	938.6M	721.9M	562.5M	165.3M	218.1M
Other Stockholder Equity	1.1B	1.3B	1.3B	1.5B	1.5B	1.6B
Total Liab	204.8M	441.2M	346.6M	267.6M	82.4M	73.5M
Short Long Term Debt Total	44.4M	42.1M	48.1M	43.1M	38.1M	30.0M
Other Current Liab	21.3M	30.7M	28.4M	33.4M	27.9M	29.3M
Total Current Liabilities	69.9M	143.5M	127.9M	111.7M	47.7M	34.0M
Property Plant And Equipment Net	107.2M	112.4M	124.7M	125.5M	52.9M	29.2M
Accounts Payable	6.7M	12.6M	9.8M	22.4M	15.3M	16.0M
Cash	80.4M	131.3M	178.9M	100.4M	45.2M	45.0M
Non Current Assets Total	232.0M	278.9M	323.2M	262.2M	71.0M	68.1M
Non Currrent Assets Other	4.0M	7.9M	10.2M	12.3M	16.6M	17.5M
Cash And Short Term Investments	385.0M	692.0M	464.7M	277.6M	81.0M	77.0M
Net Receivables	37.6M	6.3M	6.4M	4.5M	1.3M	1.3M
Common Stock Total Equity	1.2M	1.4M	1.5M	1.7M	1.5M	1.4M
Short Term Investments	282.0M	510.1M	197.7M	177.2M	35.8M	34.0M
Non Current Liabilities Total	134.9M	297.6M	218.7M	155.8M	34.7M	57.7M
Property Plant And Equipment Gross	107.2M	112.4M	149.7M	162.1M	103.9M	109.1M
Total Current Assets	405.5M	659.7M	398.8M	300.3M	94.3M	175.7M
Accumulated Other Comprehensive Income	(2.4M)	5.4M	(4.0M)	(8.4M)	(4.6M)	(4.4M)
Common Stock	1.2M	1.4M	1.5M	1.7M	1.8M	1.7M
Net Debt	(36.0M)	(89.2M)	(130.8M)	(57.3M)	(7.1M)	(7.5M)
Other Current Assets	5.4M	12.0M	15.9M	18.2M	12M	12.6M
Property Plant Equipment	29.9M	41.3M	51.5M	63.5M	73.1M	76.7M
Current Deferred Revenue	38.7M	96.6M	85.7M	51.8M	59.5M	62.5M
Intangible Assets	53.2M	58.1M	53.8M	50.7M	58.3M	61.3M
Other Liab	93.7M	259.2M	174.6M	116.9M	134.4M	141.1M
Net Tangible Assets	340.1M	397.3M	281.9M	206.7M	237.7M	227.0M
Retained Earnings Total Equity	(657.0M)	(778.0M)	(956.3M)	(1.1B)	(1.0B)	(982.0M)
Capital Surpluse	1.1B	1.3B	1.3B	1.5B	1.7B	873.1M
Inventory	(22.5M)	(50.5M)	(88.2M)	1.0	0.9	0.95
Deferred Long Term Liab	6.6M	7.2M	6.6M	6.3M	7.2M	9.3M

Currently Active Assets on Macroaxis

GM	General Motors
S	SentinelOne
MSFT	Microsoft
C	Citigroup
F	Ford Motor

When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:

How To Invest In Sangamo

Details

Is Sangamo Stock a good investment?

Details

What is Sangamo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Sangamo Stock analysis

When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Bonds Directory Find actively traded corporate debentures issued by US companies
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories

Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.48)

Revenue Per Share

1.01

Quarterly Revenue Growth

(0.93)

Return On Assets

(0.18)

Return On Equity

(1.36)

The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sangamo Non Current Liabilities Total vs Total Current Liabilities Analysis

Non Current Liabilities Total vs Total Current Liabilities

Non Current Liabilities Total vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Total Current Liabilities

Sangamo Therapeutics fundamental ratios Correlations

Sangamo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sangamo Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Sangamo Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Current Liabilities	+ 0.99	Total Liab
Common Stock	+ 0.99	Common Stock Total Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Non Currrent Assets Other	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Net Debt	- 0.94	Cash
Other Current Assets	- 0.88	Retained Earnings
Accounts Payable	- 0.87	Retained Earnings